中医药减毒增效作用在免疫检查点治疗中的应用进展
The attenuating and potentiating effects of traditional Chinese medi-cine in immune checkpoint therapy
张志鹏 1陈子琦 2田建辉3
作者信息
- 1. 上海中医药大学附属市中医医院肿瘤研究所,上海 200071
- 2. 上海中医药大学附属市中医医院实验中心,上海 200071
- 3. 上海中医药大学附属市中医医院肿瘤研究所,上海 200071;上海中医药大学附属市中医医院肿瘤临床医学中心,上海 200071
- 折叠
摘要
免疫治疗已成为癌症临床实践与科学研究中的全球瞩目焦点.近两年尤以Nivolumab、Pem-brolizumab、Atezolizumab 和 Ipilimumab 为代表的PD-1\PD-L1和CTLA-4抑制剂,针对免疫检查点在肿瘤免疫调节中的作用已在非小细胞肺癌、结肠癌、黑色素瘤和尿道癌等恶性肿瘤中取得了令人振奋的成果.中医药在中国有着悠久的历史,调控免疫检查点治疗恶性肿瘤具有一定优势,并且改善其不良事件也表现出较好的疗效.本文综述了中医药在调控免疫检查点和改善不良反应中的作用及其在免疫调节治疗中的应用前景.
Abstract
Immunotherapy has become a global focus in cancer clinical practice and scientific re-search.In the past two years,PD-1\PD-L1 and CTLA-4 inhibitors,especially Nivolumab,Pembrolizumab,Atezolizumab and Lpilimumab,have been used in non-small cell lung cancer,colon cancer.Promising results have been obtained in malignancies such as melanoma and urinary tract cancer.Traditional Chi-nese medicine has a long history in China.Modulat-ing immune checkpoints has certain advantages in treating malignant tumors,and it has shown good efficacy in improving its adverse events.This article reviews the role of traditional Chinese medicine in regulating immune checkpoints and improving ad-verse reactions and its application prospects in im-munomodulatory treatment.
关键词
中医药/恶性肿瘤/免疫检查点/免疫治疗/不良反应Key words
traditional Chinese medicine/malig-nant tumours/immune checkpoint/immunothera-py/adverse reaction引用本文复制引用
基金项目
上海市炎癌转化病证生物学前沿研究基地(2021科技03-12)
上海市中医医院未来计划科技发展项目(WL-HBRC-2021001K)
上海市卫生健康领军人才(2022LJ014)
国家自然科学基金面上项目(81973517)
国家自然科学基金面上项目(82174245)
出版年
2024
国家科技期刊平台
NSTL
万方数据